Bausch Health Companies Inc. (TSE:BHC - Free Report) - Zacks Research upped their Q1 2024 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Tuesday, April 2nd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.05 per share for the quarter, up from their previous forecast of $1.04. The consensus estimate for Bausch Health Companies' current full-year earnings is $4.97 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2025 earnings at $1.54 EPS and FY2025 earnings at $5.35 EPS.
Bausch Health Companies (TSE:BHC - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported C$1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of C$1.36 by C$0.19. Bausch Health Companies had a negative return on equity of 686.52% and a negative net margin of 6.76%. The company had revenue of C$3.28 billion for the quarter, compared to analyst estimates of C$3.05 billion.
Separately, Royal Bank of Canada boosted their price target on Bausch Health Companies from C$8.00 to C$9.00 and gave the company a "sector perform" rating in a report on Friday, February 23rd.
View Our Latest Stock Report on BHC
Bausch Health Companies Stock Up 0.2 %
Shares of BHC traded up C$0.03 during trading on Thursday, reaching C$13.63. The company's stock had a trading volume of 372,117 shares, compared to its average volume of 339,398. Bausch Health Companies has a twelve month low of C$7.56 and a twelve month high of C$15.43. The company has a quick ratio of 0.58, a current ratio of 1.30 and a debt-to-equity ratio of 7,583.76. The company has a market cap of C$4.98 billion, a price-to-earnings ratio of -6.20, a P/E/G ratio of 0.21 and a beta of 0.83. The company has a fifty day moving average of C$12.27 and a two-hundred day moving average of C$10.96.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Articles
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
